Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung‐Jue Bang, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Eric Van Cutsem, Rui‐Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon‐Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan M. Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani